×

RNS Number : 1775F

Nanoco Group PLC

10 November 2015

 

This release replaces the RNS Reach announcement released at 7am this morning due to an issue with the LuxLive website link in the earlier release.

For immediate release

10 November 2015

 

RNS REACH

 

 

 

NANOCO GROUP PLC

("Nanoco" or "the Company")

 

Presentation at LuxLive and Strategies in Light Conferences

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that it will be presenting at LuxLive and Strategies in Light Conferences. The event will be held between 17-19 November 2015 in London, United Kingdom.

 

Steve Reinhard, Vice President Business Development, will be delivering a presentation on "Light People Like" that explores the progress of cadmium-free quantum dots in the lighting industry and the technology's potential to address unmet requisites for "natural" colour.

 

Nanoco and its partner Marl International, a pioneer of the LED lighting industry, will be demonstrating four product lines based on Nanoco's CFQD® quantum dot film technology. These products will showcase CFQD® Quantum Dot technology as a revolutionary solution for high-end lighting applications in retail and specialty, architecture, and agriculture, where maintaining true-to-life colour representations maximizes user experience and value.

 

Nanoco will also display its patent-pending Deep Red CFQD® quantum dot film for horticultural applications, designed to promote the propagation and vegetative stage of plant growth and stimulate greater chlorophyll absorption – important for higher yielding plants.

 

Further details about LuxLive and Strategies in Light Conferences are available at this link: http://luxlive.co.uk/   

 

 

Michael Edelman, Nanoco's CEO, commented: "We are delighted to participate at this year's LuxLive and Strategies in Light Conferences. Our presentations will explain how Nanoco's cadmium free quantum dots will revolutionise colour in lighting. Nanoco's applications in lighting have gained momentum this year and we look forward to continuing our progress in this area."

 

 

For further information, please contact:

 

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer Caroline Watson, Investor Relations Manager cwatson@nanocotechnologies.com	Tel: + 44 (0) 7799 897357
Canaccord Genuity – Joint Broker	Tel: +44 (0) 20 7523 8000
Simon Bridges
Cameron Duncan Mark Whitmore
Liberum – Joint Broker	Tel: +44 (0) 20 3100 2000
Neil Patel
Richard Bootle Steven Tredget
Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAFFFFSSFISEEF

Close

×

RNS Number : 6225E

Oxford Pharmascience Group PLC

05 November 2015

 

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

 

Successful Completion of Proof-of-Concept for OXPzeroTM Ibuprofen

 

Following the successful completion of the second study with OXPzeroTM Ibuprofen, the Company is pleased to announce that it has established a robust body of data which it will use to progress into partnering discussions for the application of the Company's OXPzeroTM technology to ibuprofen.

The body of data collected across the two studies demonstrate that OXPzeroTM Ibuprofen is a differentiated, superior form of ibuprofen delivering a range of benefits over the standard drug across multiple parameters. In particular, OXPzeroTM Ibuprofen has been proven to:

–     deliver major reduction in the incidence and severity of gastrointestinal (GI) mucosal damage;

–     completely taste mask the bitterness of ibuprofen; and

–     deliver an attractive PK profile with immediate and complete drug release.

The Company believes these benefits offer major competitive advantages and strongly position OXPzeroTM Ibuprofen to become a disruptive compound in the worldwide ibuprofen market. Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector with worldwide sales of Ibuprofen in excess of $4bn per annum. The Company has initiated contact with a number of large, global pharmaceutical companies with strategic interest in the ibuprofen market and is at an advanced stage of preparing information to proceed to the commercialisation phase with the OXPzeroTM Ibuprofen asset.

Marcelo Bravo, Chief Executive Officer, commented:

 

"We are very pleased with the data package on OXPzeroTM Ibuprofen which demonstrates this is a compound with potential to disrupt the market, delivering a range of key benefits that provide clear and compelling differentiation.  The body of data shows this is a versatile and flexible technology that can allow major brand owners to create and sustain competitive advantage in the large and growing ibuprofen market through multiple brand extension options. In the coming weeks, we will be completing preparation of commercial discussion materials with the aim of seeking a partner for the OXPzeroTM Ibuprofen platform. We look forward to updating shareholders in due course.

We continue making great progress with other key NSAIDs, namely OXPzeroTM Naproxen, OXPzeroTM Diclofenac and OXPzeroTM Aspirin and also evaluating further targets.  Additional announcements will be made as appropriate."

 

Background

The Company has conducted two proof-of-concept studies with OXPzeroTM Ibuprofen, each performed with average prescription doses of ibuprofen (2 x 400mg tablets three times per day i.e. 2.4g per day) in healthy subjects:

·    Study 1 – OXP001-002: (performed and reported in 2014) PK and endoscopy study with a standard oral 400 mg tablet with OXPzeroTM Ibuprofen vs. Brufen® in 43 healthy subjects.

·    Study 2 – OXP001-003:  Two part study. Part 1 PK study in 10 healthy subjects reported in August 2015. Part 2 PK and endoscopy study in 43 healthy subjects commenced in August 2015 and now complete. Both parts of the study were performed with a chewable tablet of optimised OXPzeroTM Ibuprofen vs. Brufen®. PK assessments after single dose in Part 1. In Part 2, PK assessments were made on Days 1 and 7 with endoscopy assessments on Day 8.

 

Endoscopy data confirms major reduction in the incidence and severity of GI mucosal damage

Data from both studies show a consistent, positive trend for OXPzeroTM Ibuprofen through a reduction in the incidence and severity of GI mucosal damage when compared to the Brufen reference.

–   OXPzeroTM Ibuprofen exhibited major reductions in the incidence of severe GI mucosal damage (Lanza score ≥3) vs Brufen® ranging from 59% in Study 1 to 36% in Study 2. These are large reductions in the "severe" end of the Lanza scale, namely subjects with over 10 erosions and/or ulcers, demonstrating a clear impact for OXPzeroTM Ibuprofen. Based on odds ratios of 0.16 and 0.43, there is 5.9 to 2.2 times greater likelihood of having Lanza ≥ 3 in the Brufen® group than in the OXPzeroTM Ibuprofen group.  

–     OXPzeroTM Ibuprofen reduces the odds of a higher Lanza score by approximately 50% to 80% based on odds ratios of 0.17 and 0.46. 

–    OXPzeroTM Ibuprofen exhibited reductions in the overall mean Lanza score by between 0.9 (p = 0.006) in Study 1 and 0.3 (p = 0.185) in Study 2.  

Between Study 1 and Study 2, the comparator Brufen® arm exhibited the biggest changes in absolute levels of GI irritation, with a reduction observed in the second study compared to the first.  This demonstrates the variance in these relatively small studies which accounts for the loss of statistical significance in the endoscopy endpoint measures in the second study.  Endoscopy efficacy measures were comparable between the OXPzeroTM Ibuprofen products tested in both studies. Further, the lack of correlation between PK (AUC, Cmax, Tmax) and GI damage across studies and treatment groups was confirmed, indicating that the GI irritation reduction seen in Study 1 was not PK dependent, validating the reduction in GI mucosal damage results seen in study 1. 

 

The Company is of the view that the data overall demonstrates that OXPzeroTM Ibuprofen is delivering major reduction in GI mucosal damage and presents an attractive profile for commercialisation.

Superior taste masking

The taste masking benefit of OXPzeroTM Ibuprofen was demonstrated using subject interviews with the chewable tablet of ibuprofen during Study 2. Consistent feedback was received confirming that the chewable tablets were tasteless, with little of the burn or after-taste issues associated with standard ibuprofen. 90% of subjects stated that there was no bitter taste after chewing the OXPzeroTM Ibuprofen tablets. These results highlight the ability of the OXPzeroTM technology to taste mask the ibuprofen by trapping it within the layers of the OXPzeroTM matrix until the drug is released in the stomach.

Attractive PK Profile

PK results from Study 2 show complete and rapid drug release with prolonged T1/2 (the time taken to reach half of peak concentration). PK data also show Tmax (time to reach maximum serum concentration) and AUC (Area Under the Curve or total drug exposure over time) comparable to Brufen®, confirming that OXPzeroTM Ibuprofen used in Study 2 is a product with immediate and complete drug release characteristics. While the PK profile of OXPzeroTM Ibuprofen is comparable to Brufen® on these measures, the maximum level of drug concentration in plasma (Cmax) is lower than that of Brufen®, but well within the therapeutic range.

The data also demonstrate that the release properties can be adapted and the Company believes that the OXPzeroTM platform technology offers the ability to adjust speed of release to meet specific product requirements. The Company believes this is an attractive PK profile with clinical advantage suitable for commercialisation.

* The modified Lanza Scale is a scoring system commonly used to describe the severity of damage to the upper gastro-intestinal tract.  The scale in this study was: Score 0 = no damage; 1 = single erosion; 2 = 2 to 9 erosions; 3 = 10 or more erosions; 4 = ulcer.  Ulcers were defined as mucosal breaks of 3mm or more demonstrating unequivocal depth. 

For further information:

Oxford Pharmascience Group Plc
Marcelo Bravo, Chief Executive	+44 20 7554 5875
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell/Jen Boorer	+44 20 7496 3000

 

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

NSAIDs are one of the most widely used classes of drugs, with combined annual sales in excess of $12bn and more than 30 million users worldwide consuming NSAIDs each day. Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector. Worldwide sales of Ibuprofen are in excess of $4bn per annum at manufacturers selling prices. Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen and diclofenac for pain and inflammation and aspirin for primary and secondary prevention of cardiovascular disease.

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCBIBLTMBIMBMA

Close

×

RNS Number : 2713E

Avanti Communications Group Plc

03 November 2015

 

3 November 2015

 

 

AVANTI COMMUNICATIONS GROUP PLC

Telkom SA Contract Win

 

Avanti Communications Group plc ("Avanti" or "the Group"), a leading provider of satellite data communications services in Europe, the Middle East and Africa, announces that it has won a contract with Telkom SA to provide national high-speed broadband coverage across South Africa.

 

Service will be supplied using Avanti's HYLAS 2 Ka-band satellite, which has 100% coverage of South Africa across five beams. This multi-year commitment is expected to make a significant contribution to filling HYLAS 2 and HYLAS 4 South African capacity in a market that is developing well for Avanti.

 

David Williams, Chief Executive of Avanti said: "It is of great importance for Avanti to secure the partnership of Telkom in our shared mission to bring broadband to all government sites, businesses and homes in South Africa. The country is Avanti's most important market and is served by HYLAS 2 and HYLAS 4. We are privileged to have been selected and look forward to a strong partnership.   Avanti has now won contracts with the incumbent national telecoms companies in all of its core African markets, in-line with its announced strategy."

 

 

For further information please contact:

Avanti: Matthew Springett, +44 (0)207 749 6703

Montfort: Nick Miles / James Olley, +44 (0)203 770 7909

Redleaf: Hannah Nicolas, +44 (0)207 382 4734

Cenkos Securities: Max Hartley (Nomad) / Julian Morse, +44 (0)207 397 8900

 

 

 

Notes to editors

Avanti connects people wherever they are – in their homes, businesses, in government and on mobiles. Through the HYLAS satellite fleet and more than 160 partners in 118 countries, the network provides ubiquitous internet service to a quarter of the world's population. Avanti delivers the level of quality and flexibility that the most demanding telecoms customers in the world seek.

 

Avanti is the first mover in high throughput satellite data communications in EMEA. It has rights to orbital slots and Ka band spectrum in perpetuity that covers an end market of over 1.7bn people.

 

The Group has invested $1.2bn in a network that incorporates satellites, gateway earth stations, datacentres and a fibre ring.

 

Avanti has a unique Cloud based customer interface that is protected by patented technology.

 

The Group has three satellites in orbit and a further two fully funded satellites under construction.

 

Avanti Communications is listed in London on AIM (AVN:LSE).

 

www.avantiplc.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTUUSVRVWAARAA

Close

×

Neville Registrars is delighted to welcome London Finance & Investment Group P.L.C. as the newest addtion to its list of client companies.

London Finance & Investment Group is a United Kingdom investment finance and management company listed on the London (Sterling Share Price) and Johannesburg (South African Rand Share Price) Stock Exchanges. Further information can be found on the Company's website: http://www.city-group.com/london-finance-investment-group-plc/

 

Close

×

RNS Number : 0978E

First Derivatives PLC

02 November 2015

 

First Derivatives plc

("FD" or the "Company")

 

Contract win with National Stock Exchange of India (NSE)

 

FD (AIM:FDP.L, ESM:FDP.I), a leading provider of software and consulting services, is pleased to announce a contract win with the National Stock Exchange of India Limited (NSE) for a range of next generation trading services, based on FD's kdb+ software platform. Following successful user testing, the system has gone live and as a result NSE is now able to provide its clients with the capability to test their algorithms before they are made live.

 

The NSE, set up in 1992, is a thought leader in the deployment of technology to improve trading practices. This contract has the potential to serve as an example towards improving the robustness of exchange trading platforms on a global basis and also in providing additional, value-added services to market participants.

 

The contract also adds a flagship global Exchange to FD's customer base in a strategically important region. Under the contract, FD will provide an Algorithmic Testing Facility which will allow NSE market participants to test the impact of their algorithms before they are deployed in production, using trade simulators to replay historical data, create market "noise" and generate extreme market shocks to fully explore the robustness and efficacy of new algorithms.

 

Ravi Varanasi, Chief, Business Development, NSE commented: "The system is expected to deliver value added services to the market participants. We can now provide Algo Test facility and accompanying data analytics to the market participants when they want it. Through individual, group and crowd tests the market participants may track an algorithm's efficiency within and across clients."

 

Brian Conlon, Chief Executive Officer of FD, commented:  "This is an important win for FD, once again referencing our software's ability to manage large volumes of real time data and, in this case, help Exchanges protect their integrity while allowing their market participants to deploy algorithms quickly and safely. We are delighted to welcome NSE as a client."

 

 

Enquiries:

First Derivatives plc	+44(0)28 3025 2242
Brian Conlon, Chief Executive Officer	www.firstderivatives.com
Graham Ferguson, Finance Director Ian Mitchell, Head of Investor Relations
Investec Bank plc (Nominated Adviser and Broker)	+44 (0)20 7597 4000
Dominic Emery
Carlton Nelson Sebastian Lawrence
Goodbody (ESM Adviser and Broker)	+353 1 667 0420
Linda Hickey Finbarr Griffin
Walbrook PR	+44 (0)20 7933 8780
Paul Cornelius/ Nick Rome/ Helen Cresswell/ Sam Allen

 

About FD

 

FD is a global technology provider with nearly 20 years of experience of working with some of the world's largest finance, technology and energy institutions. FD is the developer of the world-leading database technology kdb+. FD employs over 1,400 people worldwide and has operations in London, New York, Stockholm, Singapore, Hong Kong, Tokyo, Sydney, Palo Alto, Toronto, Philadelphia, Dublin, Belfast and its headquarters in Newry.

 

For further information, please visit www.firstderivatives.com

 

About National Stock Exchange of India

 

In its 20 year history, NSE has transformed the capital market, based on technology, innovation and high standards of governance and management practices. NSE's business practices, product innovation and high levels of integrity have earned it the trust of the financial market worldwide. Besides being a platform of choice for all exchange traded financial products in India, NSE's flagship index, the Nifty 50, has become a benchmark as a national level economic parameter. According to the World Federation of Exchanges' ratings, NSE is the largest exchange in the world in currency options and index options and third largest in cash market trade. Among the many accolades won by the exchange, the recent and coveted CII-EXIM Bank Prize for Business Excellence is a recognition of this remarkable journey.

For further information, please visit www.nseindia.com

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTMMMFGVGLGKZM

Close

×

RNS Number : 8380D

Fastjet PLC

29 October 2015

 

fastjet Plc

("fastjet" or the "Company")

29 October 2015

fastjet Zimbabwe's inaugural flight

 

fastjet (AIM:FJET), Africa's low-cost airline, is pleased to confirm that the first flight of its subsidiary fastjet Zimbabwe, between Harare and Victoria Falls, took place yesterday. This marks the successful launch of a new low-cost Zimbabwean airline and the second fastjet airline.

 

fastjet Zimbabwe's first flight departed Harare International Airport with dignitaries, government officials, media and local passengers on board. Upon arrival at Victoria Falls International Airport, the flight was welcomed by the Mayor of Victoria Falls and the return flight landed in Harare to an official launch ceremony.

 

fastjet Zimbabwe will initially fly between Harare and Victoria Falls three times a week on Wednesdays, Fridays, and Sundays, with more flights being added as demand increases.

 

The Zimbabwe Government has designated the airline on routes to South Africa, Botswana and Malawi.  Further designations to Zambia, Democratic Republic of Congo, Kenya, Namibia and Mozambique are all expected to be granted over the coming weeks.

 

Commenting, fastjet Chief Executive Officer Ed Winter said: "Today is a momentous day for fastjet as we launch fastjet Zimbabwe, our second low-cost airline in Africa, allowing even more people to enjoy safe, reliable, convenient and affordably priced air travel."

 

 

For more information, contact:

 

fastjet Plc	Tel: +44 (0) 20 3651 6307
Ed Winter, Chief Executive Officer
Rose Herbert, Investor Relations Manager
UK media – Citigate Dewe Rogerson	Tel: +44 (0) 20 7638 9571
Angharad Couch
Eleni Menikou
Nick Hayns
South African media – Tribeca Public Relations	Tel: +27 (0) 11 208 5500
Cian Mac Eochaidh
Kelly Webster
For investor enquiries please contact:

 

Liberum Capital Limited – Nominated Adviser and Joint Broker	Tel: +44 (0) 20 3100 2222
Clayton Bush
Christopher Britton
W.H. Ireland Ltd.- Joint Broker	Tel: +44 (0) 20 7220 1666
James Joyce
Mark Leonard
Sanlam Securities UK Limited – Joint Broker	Tel: +44 (0) 20 7628 2200
Simon Clements/Ken Williams

 

 

 

NOTES TO EDITORS

 

About fastjet Plc

 

fastjet Plc is the holding company of the low cost airline fastjet which commenced flights under the fastjet brand in Tanzania in November 2012. By adhering to international standards of safety, quality, security and reliability, fastjet has brought a new flying experience to the African market at unprecedented low prices. Utilising its fleet of Airbus A319s, fastjet is implementing the low-cost model across Africa and its long-term strategy is to become the continent's first low-cost, pan-African airline.

 

The results of a customer satisfaction survey showed that 100% of customers were likely to recommend fastjet to a friend. In developing its strong brand and identity, fastjet has won and been nominated for a number of awards, including winning three Transform awards for the rebrand and launch of fastjet, the award for "Brand Strategy of the Year" at 2014's Drum Marketing Awards in London, and the Transport Innovator Award at the 8th Transport Africa Awards 2015 in Johannesburg.

 

fastjet Plc is quoted on the London Stock Exchange's AIM Market.

 

For more information see www.fastjet.com.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAGIBDGCSDBGUC

Close

×

RNS Number : 8962C

Transense Technologies PLC

21 October 2015

 

 Transense Technologies PLC

("Transense", the "Company" or the "Group")

 

Sale of IntelliSAW Division for US$5m

 

Transense is pleased to announce that it has agreed to sell the business (net assets and goodwill) of IntelliSAW, and receive a one-off license fee as part of the transaction to secure exclusive use of Transense Technologies' IP relating to the IntelliSAW business, to US-based Emerson, a diversified global manufacturing company, for a total cash consideration of US$5m. The total sum payable to Transense Technologies net of all costs will be approximately £2.9m.

The sale of IntelliSAW, plus the proceeds raised from the recent placing and offer, provide Transense with a strong cash position, which will be used to accelerate commercial  developments in the two remaining divisons, Translogik and SAWSense. The Transense Group (excluding IntelliSAW) has already achieved a positive EBITDA in both H1 and the full year to 30 June 2014, and with the consequential reduction in monthly Group overhead run-rate, the sale moves the Group significantly closer to breakeven. The IntelliSAW division had a net loss in the year to June 2015 of £1.04m (2014: £0.96m).

Graham Storey, CEO of Transense, commented "The sale of the IntelliSAW division, to a company of the standing of Emerson, is another demonstration of the commercial value of our technology. This provides Emerson with a unique opportunity to strengthen and grow this business. I am grateful to the employees of IntelliSAW for their commitment to growth and operational excellence throughout our partnership. We now have a considerably strengthened balance sheet, and believe that the Group is well positioned to become a self-sustaining, high-growth and cash-generative business. "

 

About Emerson

Emerson, based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions to customers in the industrial, commercial and consumer markets around the world. The company is comprised of five business segments: Process Management, Industrial Automation, Network Power, Climate Technologies, and Commercial & Residential Solutions. Sales in fiscal 2014 were US$24.5 billion. For more information, visit www.Emerson.com.

 

http://www.emerson.com/

 

 

About Transense Technologies

Based in Oxfordshire, UK, Transense has developed patent-protected sensor systems and supporting technology for use in a variety of diverse high growth markets. Transense's Surface Acoustic Wave (SAW), wireless, battery-less, sensor systems offer significant advantages over legacy wireless sensor systems. Transense is targeting the transport and mining industries, and the global torque, temperature and pressure sensing markets, via its trading divisions Translogik and SAWSense, respectively.

Transense's shares are admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: "TRT").

 

www.transense.co.uk

 

For further information, please contact:

 

Transense Technologies plc – Tel: +44 1869 238 380

Graham Storey, Chief Executive

 

finnCap – Tel: +44 20 7220 0500

Ed Frisby, Giles Rolls (corporate finance)

Tony Quirke, Alice Lane (corporate broking)

 

IFC Advisory – Tel: +44 20 3053 8671

Tim Metcalfe, Graham Herring

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

DISFBLLLEBFFFBE

Close

×

RNS Number : 5913C

Wynnstay Group PLC

19 October 2015

 

 

19 October 2015

AIM:WYN

 

Wynnstay Group plc

("Wynnstay" or "the Group" or "the Company")

 

Expansion into New Trading Area with Acquisition of Agricentre

& Trading Update

 

Wynnstay, the agricultural and retail group, is pleased to announce that it has reached agreement with T. G. Jeary Ltd on terms for the acquisition of its West Country farm supplies operation, Agricentre, and certain related assets ("Agricentre" or the "Acquisition"). The Company expects to enter into a legally binding agreement for the Acquisition shortly with a view to completing the Acquisition on 30 October 2015. Wynnstay will utilise its existing banking facilities to fund the Acquisition. The terms of the Acquisition are not being disclosed for commercial reasons.

Established in 1961, Agricentre operates a network of eight units supplying a wide range of agricultural inputs including animal healthcare, dairy hygiene and animal nutrition products as well as feed related equipment and other hardware. Its units are located in Bristol, Calne, Langport, Honiton, Salisbury, Shepton Mallet, Sturminster Newton and the Isle of Wight. Agricentre has historically generated annualised sales of approximately £15 million and for the current financial year is expected to show a small operating loss.

The Acquisition is an important strategic move for Wynnstay, extending the Group's trading presence into a major new geographic region. Wynnstay expects to integrate the business into its existing stores network and to significantly enhance Agricentre's product range and operational efficiencies. However the full benefits of the Acquisition are not expected to come through for 12 months. 

Wynnstay is also pleased to report that following satisfactory trading in the second half of the financial year to date, final results for the 12 months to 31 October 2015, before acquisition costs, are expected to be in line with market expectations. Looking ahead, the trading backdrop for farmers remains difficult and Wynnstay is taking a cautious view on the expected recovery in output prices over the next twelve months. The investment programme in the business is progressing well and underpins the Group's continuing development. 

Ken Greetham, CEO of Wynnstay Group, said:

"Agricentre has been supplying farmers in the West Country with agricultural inputs for 54 years and I am delighted to announce that we have agreed terms to acquire the business. It is a strategically important move for us as it extends Wynnstay into a new trading area. We look forward to working with the existing management team to further develop the business and bring new products and services to their customer base.

UK farmers are currently facing challenges, with low farmgate prices particularly for milk. While the trading backdrop remains challenging, we remain positive about the long term opportunities driven by world food demand, and continue to focus on assisting farmers with the drive for enhanced efficiencies in production."

 

Enquiries:

 

Wynnstay Group plc	Ken Greetham, Chief Executive Paul Roberts, Finance Director	T: 01691 827 142
KTZ Communications	Katie Tzouliadis	T: 020 3178 6378
Shore Capital (Nomad)	Stephane Auton / Patrick Castle	T: 020 7408 4090

 

 

About Wynnstay Group plc

www.wynnstaygroup.co.uk

 

Headquartered in Wales, Wynnstay manufactures and supplies agricultural inputs, including animal nutrition products, seeds, fertiliser and agro-chemicals, to livestock and arable farmers. Its activities also include the supply of raw materials for feeds ingredients to farmers and other feed manufacturers, and the provision of grain trading services for farmers.  Its specialist retailing activities comprise Wynnstay Stores, a network of country stores  catering for farmers and the wider rural community, Youngs Animal Feeds, a manufacturer and distributor of equine products, and Just for Pets, a chain of pet products stores based across the West Midlands.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCPKADPPBDDPKD

Close

×

RNS Number : 0567C

Nanoco Group PLC

13 October 2015

 

For immediate release

13 October 2014

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company") 

 

Signs follow-on Joint Development Agreement with Osram

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that it has signed a further follow-on joint development agreement with Osram, one of the world's largest lighting companies, in connection with the use of Nanoco quantum dots in lighting.

 

Nanoco has been working with Osram under joint development agreements since 2011 with the objective of delivering LED lighting with superior performance characteristics.  Much of the technical work to date has focused on encapsulating Nanoco's cadmium-free quantum dots to optimise them for the operating conditions associated with LEDs.

 

Nanoco's cadmium-free quantum dot technology has the potential to transform LEDs so that they more efficiently produce bright, warm light with the ability to accurately reproduce colours.

 

Michael Edelman, Nanoco's Chief Executive Officer, said: "We're delighted to sign this latest joint development agreement with Osram and to continue this exciting work focused on creating LEDs with substantially improved colour performance.  Lighting is a core target market for our cadmium-free quantum dot technology."

 

 

 

For further information, please contact:

 

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer
Canaccord Genuity – Joint Broker	Tel: +44 (0) 20 7523 8000
Simon Bridges Cameron Duncan
Mark Whitmore
Liberum – Joint Broker	Tel: +44 (0) 20 3100 2000
Neil Patel
Richard Bootle Steven Tredget
Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCMJBATMBJBMRA

Close

×

RNS Number : 0564C

1PM PLC

13 October 2015

 

 

 

13 October 2015

1PM PLC

(AIM: OPM)

 

1pm wins top awards at the 2015 Annual Leasing World Awards

 

1pm plc ("1pm" or "the Company"), the AIM listed independent provider of finance facilities to the SME sector, is delighted to announce that at the seventh Annual Leasing World Awards 2015, held recently at The Whitehall Suite, One Whitehall Place, London SW1, the Company won Independent Lessor of the Year, and COO, Maria Lewis was presented with the Editor's Choice award.

 

The Annual Leasing World Awards have quickly become established as a leading showcase for the best performing companies and individuals within the UK Leasing industry, providing an opportunity to recognise outstanding achievement across a range of categories, including UK Lessor of the Year, Innovator of the Year and SME Champion of the year. The event was sponsored for the third consecutive year by Hitachi Capital Business Finance.

 

Commenting on these latest successes, Ian Smith, Chairman of 1pm said:

"These awards are deserved recognition of the Company's continued outstanding commercial and financial performance which has seen the business more than double in size in recent years. This has been driven by the executive team of Maria Lewis and Helen Walker, supported by the entire staff."  

 

Enquiries:

1pm plc	www.1pm.co.uk
Maria Lewis, COO	0844 967 0944
Helen Walker, Finance Director	0844 967 0944
Walbrook PR Limited	0117 985 8989
Paul Vann	07768 807631
	paul.vann@walbrookpr.com

About 1pm:

 

The Company was admitted to AIM in August 2006.

 

1pm plc is an established independent finance company focused on providing SMEs with accessible funding to add value to their businesses.  All customers must have good credit histories and proven ability to repay their finance commitments.

 

1pm currently provides assets finance from £1,000 to £50,000 for a period of between 12 and 60 months and £1,000 to £50,000 for business loans (repaid over 3-36 months).

 

Mission Statement – 'Helping the UK economy grow by providing funding to businesses'

 

More information is available on the Company website www.1pm.co.uk

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALIFLEIFLVLIE

Close